Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Lee

Urology Arlington, TX Medical Doctor

NPI 1023004413 CMS profile 91933

5005 S Cooper St Ste 250, Arlington, TX 76017

Open in the dashboard

General payments

$9,443

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Lee of Arlington, TX is reported in the CMS Open Payments database as having received $9,443 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,353 54
2024 General $1,706 30
2023 General $929 50
2022 General $772 57
2021 General $789 30
2020 General $301 17
2019 General $595 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Lee
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Justin Lee were reported at $4,353. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Justin Lee Urology median Middle half National median
2019 $595 $480 $147–$1,201 $163
2020 $301 $246 $87–$645 $114
2021 $789 $358 $111–$1,000 $132
2022 $772 $476 $143–$1,263 $149
2023 $929 $560 $168–$1,461 $160
2024 $1,706 $563 $170–$1,464 $164
2025 $4,353 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,495 20 payments
  2. Janssen Biotech, Inc. $401 16 payments
  3. AbbVie, Inc. $386 22 payments
  4. Boston Scientific Corporation $357 6 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $354 18 payments
  6. Dendreon Pharmaceuticals LLC $313 12 payments
  7. Sumitomo Pharma America, Inc. $305 34 payments
  8. Merck Sharp & Dohme Corporation $245 9 payments
  9. Urovant Sciences Inc $235 35 payments
  10. Immunitybio, Inc. $231 8 payments
  11. Other $2,122 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,169 251 payments
  2. Travel and Lodging $4,161 14 payments
  3. Grant $114 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $4,495 20 payments
  2. GEMTESA $480 66 payments
  3. ERLEADA $366 14 payments
  4. Nubeqa $354 18 payments
  5. PROVENGE $313 12 payments
  6. LUPRON DEPOT $304 17 payments
  7. Xofigo $257 13 payments
  8. KEYTRUDA $245 9 payments
  9. ANKTIVA $231 8 payments
  10. Kerecis Omega3 SurgiClose $224 2 payments
  11. Other $3,622 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

678

Median for Urology: 1,053

Drug cost

$60,754

Median for Urology: $101,464

Branded share of claims

36.7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 51 $36,895
Myrbetriq Mirabegron Brand 23 $12,378
Tamsulosin Hcl Generic 227 $3,961
Finasteride Generic 94 $1,635
Testosterone Cypionate Generic 28 $1,546
Alfuzosin Hcl Er Alfuzosin Hcl Brand 38 $1,272
Oxybutynin Chloride Er Oxybutynin Chloride Brand 84 $1,250
Solifenacin Succinate Generic 11 $417
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 20 $406
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $351

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$91,696

Medicare's payments for the services billed

Medicare patients

392

Average age 73

Services billed

2,725

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 74%
Arthritis 37%
Ischemic heart disease 28%
Diabetes 25%
Chronic kidney disease 17%
Atrial fibrillation 16%
Depression 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $129
$129 — —
POSLUMA
  • Blue Earth Diagnostics Limited $59
$59 — —
AKEEGA
  • Janssen Biotech, Inc. $58
$58 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $41
$41 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record